Gedeon Richter withdraws Efgratin’s EMA registration application

…within the given timeframe. However, the company claims to reserve its right to make further submissions in the future either in the same therapeutic indications or in others. Efgratin was developed to treat certain side effects associated with cancer patients in receipt of chemotherapy.

Sign up now to open the entire news item.

You are allowed to open only one news item from PMR websites.
  • 1E-mail
    (to send requested information)
  • 2Brief profile
    (required for new e-mails only)

 required fields

You must accept PMR’s Privacy Policy.